Starpharma's drug delivery program with Lilly advances
Starpharma today announced the advancement of its drug delivery collaboration with US pharmaceutical corporation Eli Lilly and Company.
Starpharma SPP closes heavily oversubscribed; completing $35m financing
Starpharma today announced that its Share Purchase Plan (SPP) which closed on Wednesday 7 December 2011, is oversubscribed by more than 400%. The SPP was capped at $3 million, and shareholders have subscribed a total in excess of $12 million.
Herald Sun: Small fry happy to follow the right moves
Herald Sun Journalist John Beveridge takes a close look at why M&G made a significant investment in Starpharma and what it could mean for other buyers: ‘If you see a clever investor grabbing a stake in a company, there is no problem piggy-backing on their research and following them on board.’
Go to the article (external link)
Australian Financial Review: Funds pick up beaten down retail
Australian Financial Review Journalist Brendon Lau investigates the activity of fund managers across a number of key stocks: Emerging biotech Starpharma Holdings has also found itself in demand by institutional investors in the wake of its recent capital raising.
The stock could re-rate, just as Mesoblast did, because M&G – one of the largest UK investment funds that is owned by Prudential Group – bought a 6.7 per cent stake in Starpharma.
M&G also became a major shareholder in Mesoblast in December last year and the stock has rallied around 80 per cent since.
Wall Street Journal: UK’s M&G bets on Aussie anti-HIV gel
Wall Street Journal Reporter Gillian Tan investigates M&G’s stake in Starpharma: ‘M&G emerged with a 6.7 per cent stake in the company after participating in Starpharma’s $32m oversubscribed institutional placement which raised funds to –among other things — accelerate the commercialisation of its VivaGel product which will include a New Drug Application filing with the United States’ Food and Drug Administration.’
Go to the article (external link)
M&G Substantial Shareholder Notice
M&G has today lodged a substantial shareholder notice with the ASX advising a 6.7% shareholding in Starpharma following their investment of AUD$20 million in the Share Placement announced last week.
Starpharma secures European (EMA) agreement on BV treatment Phase 3
Starpharma today announced that the Phase 3 clinical trial program for VivaGel® bacterial vaginosis (BV) treatment has now also been agreed with the European Medicines Agency (EMA).
Australian Financial Review: Starpharma’s ‘deep portfolio’ attracts investors
Australian Financial Review Journalist Claire Stewart investigates Starpharma’s continued resilience in a difficult market, noting the significance of its $32m capital raising at market price: As market volatility shakes investors’ confidence, the share prices of many research and development-focused companies are suffering as a result of increasing concerns about capital availability and funding issues.
But for Starpharma, a $260 million pharmaceutical company that develops polymer – or dendrimer – nanotechnology, equity has not been an issue.
This week it raised $32 million through a share placement to institutional investors and it will launch a retail share purchase plan to raise an additional $3 million, opening on November 23.
Australian Life Scientist: Starpharma raises $32m
Australian Life Scientist notes the significance of M&G’s investment in Starpharma: ‘Starpharma Holdings (ASX:SPL) has raised $32 million in a placement, and will seek a further $3 million in a SPP, to help fund clinical trials and new product development.’
AAP: Investors give Starpharma $32m boost
AAP analyses how M&G’s investment will advance Starpharma’s research portfolio: ‘A $32 million cash injection has given a boost to biotech Starpharma's plans to carry out advanced tests of a treatment for a common bacterial infection in women.